Patents by Inventor Michael Spitzenberg

Michael Spitzenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
    Patent number: 9145385
    Abstract: The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form as a monohydrate or anhydrate, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor).
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: September 29, 2015
    Assignee: Sanofi
    Inventors: Martin Feth, Bruno Baumgartner, Michael Spitzenberg, Claudius Boehm, Norbert Nagel
  • Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
    Patent number: 9102657
    Abstract: The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid, and to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor).
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: August 11, 2015
    Assignee: Sanofi
    Inventors: Martin Feth, Bruno Baumgartner, Michael Spitzenberg, Claudius Boehm, Norbert Nagel
  • Sodium Salt Of (R)-3-[6-Amino-Pyridin-3-Yl]-2-(1-Cyclohexyl-1H-Imidazol-4-Yl)-Propionic Acid
    Publication number: 20140343106
    Abstract: The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid, and to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor).
    Type: Application
    Filed: November 22, 2012
    Publication date: November 20, 2014
    Inventors: Martin Feth, Bruno Baumgartner, Michael Spitzenberg, Claudius Boehm, Norbert Nagel
  • Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
    Publication number: 20140329864
    Abstract: The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form as a monohydrate or anhydrate, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor).
    Type: Application
    Filed: November 22, 2012
    Publication date: November 6, 2014
    Inventors: Martin Feth, Bruno Baumgartner, Michael Spitzenberg, Claudius Boehm, Norbert Nagel